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SUMMARY
Prohibiting the nonmedical use of certain
mind-altering substances has been a public
policy goal of the federal government for
more than a century.
Drug abuse is a problem in the United
States due to its economic cost, estimated to
have been over $160 billion in 2000.  This
sum includes lost productivity, health care
costs, and criminal justice expenditures.  More
than 1.5 million people are estimated to have
been arrested in the United States in 2002 for
drug abuse violations.
The U.S. government remains committed
to a policy of zero tolerance when it comes to
the use of controlled substances.  A different
approach has recently emerged in Europe and
elsewhere as governments experiment with
less restrictive policies, such as decriminaliza-
tion and “harm reduction” measures.  
Among the early actions of the 108th
Congress were passage of the remaining
appropriations for FY2003, including those
for the many federal drug control agencies and
programs, and passage of the Illicit Drug Anti-
Proliferation Act of 2003, designed to control
the use of “club drugs” such as Ecstasy.  
The House passed H.R. 2086, to
reauthorize ONDCP (the office of the “Drug
Czar”) and related programs, on September
30, 2003.  A Senate bill to extend ONDCP (S.
1860) was introduced on November 14, 2003.
Other drug control issues taken up in the
first session included drug control budget
appropriations for FY2004 and confirmation
by the Senate of a new head of the Drug
Enforcement Administration (DEA).
In its second session, the 108th Congress
is acting on the President’s budget request for
FY2005 and will likely complete its consider-
ation of ONDCP reauthorization measures.
The Hinchey-Rohrabacher Amendment
to protect medical cannabis users from federal
prosecution in the 10 states that have ap-
proved its use was debated and defeated on
the floor of the House on July 7, 2004.
H.R. 10, the House intelligence reform
bill, would create within the Department of
Homeland Security (DHS) an Office of
Counternarcotics Enforcement with broad
powers to coordinate federal policy and opera-
tions to stop the entry of illegal drugs into the
United States.
Additional issues under consideration by
the 108th Congress include measures to control
drugged driving and methamphetamine pro-
duction and trafficking.
Executive Branch actions concerning the
war on drugs that are of relevance to the 108th
Congress include the President’s drug control
strategy for FY2004, the success of the drug
war as measured by national surveys of drug
use, and actions taken by DEA against indus-
trial hemp products and medical marijuana
providers.
For related information on international
drug control legislation and issues, see CRS
Issue Brief IB88093, Drug Control: Interna-




H.R. 10, the House bill to implement the recommendations of the 9/11 Commission,
would create within the Department of Homeland Security (DHS) an Office of
Counternarcotics Enforcement, which would be headed by a director appointed by the
President, with the advice and consent of the Senate.  The responsibilities of the Director of
Counternarcotics Enforcement would be greatly expanded over those of the DHS
counternarcotics officer as created in the Homeland Security Act of 2002 (P.L. 107-296, Sec.
878).  The bill is in committee markup.  The Senate intelligence reform bill,  S. 2845, being
considered on the floor of the Senate, contains no similar provision.
BACKGROUND AND ANALYSIS
Introduction
The control of certain mind-altering substances has been a public policy goal of the
federal government and the focus of congressional legislative efforts for more than a century.
This “war on drugs,” as it has come to be known, encompasses a wide array of public
policies and programs designed to curb the use of illegal drugs by residents of the United
States and its outlying areas.
It can be said to have begun in November 1880 when an “absolute prohibition” on the
shipment of opium between the United States and China was agreed to in treaty negotiations
between the two countries.  The 49th Congress enacted implementing legislation on February
23, 1887, providing a misdemeanor fine of between $50 and $500 for any U.S. or Chinese
citizen found guilty of violating this ban.
The drug war escalated, in fits and starts, until 1971 when President Nixon declared the
modern war on drugs.  He announced “a new, all-out offensive” against drug abuse,
“America’s public enemy number one,” and created a new office directly under him in the
White House to coordinate the major federal drug abuse programs.  Drug control legislation
has been actively considered by every Congress since then, and the 108th Congress is no
exception.  
The term “drug,” in this context, means a substance that is illegally taken into the body
to affect mood or behavior.  Examples include marijuana, cocaine, methamphetamine, and
heroin.  A legal pharmaceutical, when obtained by illegal means or used for nonmedical
purposes, becomes an illegal drug under this definition.  The term “controlled substance”
means a drug or other substance that is included in schedule I, II, III, IV, or V of the
Controlled Substances Act, as amended (21 U.S.C. 812).
This issue brief covers significant legislative and oversight activities of the 108th
Congress that concern domestic law enforcement aspects of federal anti-drug policy.  Also
included will be significant executive branch actions and other current developments of




Costs to Society of Illegal Drug Use.  The Office of National Drug Control Policy
estimates the economic cost of  illegal drug use in the United States to have been $160.7
billion in 2000, when some 25 million Americans used an illegal drug at least once during
the year.  This cost equals slightly more than 1.6% of that year’s gross domestic product of
$9,817.0 billion.  Losses in productivity accounted for 69% of the estimated cost of drug use.
(Incarceration was the leading cause of lost productivity, followed by crime careers, drug
abuse related illness, and premature death.)  Health care costs were estimated at 9% of the
total cost of illegal drug use.  Other costs — including drug-related expenses for police,
courts, prisons, and social welfare — made up the remaining 22% of the cost of illicit drug
use.  This breakdown reveals that a large part of the price society pays for drug use arises not
from the effects of the drugs themselves, but from the costs of enforcing the laws that
prohibit them.
Deaths from Drugs.  The number of deaths due to drug overdoses provides another,
frequently cited measure of the cost of drug use.  At congressional hearings, witnesses often
cite the number of drug-induced deaths reported annually by the Centers for Disease Control
and Prevention (CDC) to justify the drug war.  Actually, the CDC’s category “drug-induced
causes” also includes deaths from legal drugs, such as suicides and accidental deaths from
medically prescribed drugs.  The most recent CDC report (“Deaths: Final Data for 2001,”
National Vital Statistics Reports, September 18, 2003, p. 11) says that 21,683 persons died
of “drug-induced causes” in the United States in 2001.  CDC is unable to provide a further
breakdown of this number by substance involved, nor are reliable data available elsewhere.
The only substance-related death toll that CDC reports separately is alcohol:  there were
19,817 deaths due to alcohol in 2001, slightly fewer than from all other drugs — legal and
illegal — combined.  The number of Americans who die annually from overdoses of illegal
drugs, such as heroin and cocaine, is simply not known, but the CDC data do indicate that
it is fewer than is usually claimed and fewer than the number who die from alcohol-induced
causes.
Drugs and Crime.  The Federal Bureau of Investigation (FBI) reports that in 2002,
of the 14,054 homicides in which the circumstances were known, 657 murders (4.7%) were
narcotics related.  In 1997, according to the Department of Justice’s Bureau of Justice
Statistics, 19% of state prisoners and 16% of federal prisoners committed their current
offense to obtain money for drugs.  The FBI estimates that more than 1.5 million people were
arrested in the United States in 2002 for drug abuse violations.  Nearly one in four persons
held in U.S. jails and prisons in 2000 was imprisoned for a drug offense.  Of the total federal
prison population in 2000, 57% was serving time for drug offenses.  The United States now
has the highest incarceration rate of all industrialized countries, due in no small measure to
the legal penalties associated with the war on drugs.
Framing the Issue
The U.S. government frames the issue as an essential effort to reduce the costs to
society of illegal drug use through vigorous enforcement of the laws that prohibit such
behavior.  The government’s attempts early in the last century to control the non-medical use
of the opiates, cocaine, and marijuana led to the passage of such laws as the Harrison
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Americans who used an illicit drug in 2002, 7.7 million or 22% needed treatment for an illicit drug
problem.  The number needing treatment is also a minority (39%) of the 19.5 million current drug
users, defined as those who used an illicit drug at least once in the past month.  (Many experts
believe the government overstates the number needing treatment but, even so, these numbers prove
the point.)  See Substance Abuse and Mental Health Services Administration, Office of Applied
Studies, Results from the 2002 National Survey on Drug Use and Health: National Findings,
NHSDA Series H-22, DHHS Publication No. SMA 03-3836, Sept. 2003, pp. 65 and 199.
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Narcotics Act in 1914 and the Marihuana Tax Act of 1937, which indirectly sought to control
drug usage through the taxation and regulatory powers of the federal government.  
After World War II, the federal government gradually took on a more central role in the
American criminal justice system.  This federalization of crime resulted in the enactment by
Congress of four major crime control measures that, as amended, guide today’s drug war:
! The Comprehensive Drug Abuse Prevention and Control Act of 1970
(P.L. 91-513); 
! The Anti-Drug Abuse Act of 1986 (P.L. 99-570);
! The Anti-Drug Abuse Act of 1988 (P.L. 100-690); and 
! The Crime Control Act of 1990 (P.L. 101-647).
The 1988 law stated: “It is the declared policy of the United States Government to
create a Drug-Free America by 1995.”  Although that ambitious and, some would say,
unrealistic goal remains unmet, the official policy remains one of zero tolerance.
Responsible drug use, unlike responsible alcohol use, is considered an oxymoron.  To use
a prohibited substance is defined as abuse, no matter how often the drug is taken, regardless
of dosage, whether or not the user is addicted.  Studies show that most drug users are not
addicts,1 yet all users of illegal drugs are subject to severe penalties and are frequently forced
into treatment, if not prison.
Under U.S. leadership, and backed by the United Nations, the drug war is global, with
the participation of every country in the world.  Recently, however, that united front has
begun to fracture.  Many European countries that have been our long-term allies in the drug
war are today beginning to frame the issue of drug abuse less as one of law enforcement and
more as one of public health.  Portugal, in 2001, decriminalized all drug use and adopted a
policy of “harm reduction.”  Spain no longer prosecutes illegal drug use done privately.
Belgium permits the use of medical marijuana.  Closer to home, Canada has legalized
marijuana for medical uses and is in the process of decriminalizing the possession of small
amounts of marijuana for personal use. The chief of the Mexican federal police has
announced his support of worldwide drug legalization as the only way to destroy the global
drug economy, and high-level officials in the government of Mexican President Vicente Fox
reportedly favor drug legalization as the solution to the violence and corruption caused by
narco-traffickers.  Even within the United States, voters in some states have approved ballot
initiatives to lessen the penalties for using certain drugs.
The federal government strongly opposes such changes.  The established policy of
prohibition is not expected to come under critical scrutiny at the federal level anytime soon.
Accordingly, today’s policy questions in Congress are mainly concerned with:
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! the priority and level of resources assigned to the drug war compared to
other pressing federal priorities (e.g., drug interdiction vs. counterterrorism);
! the relative emphasis given to each of the components of the war on drugs
(e.g., enforcement vs. treatment); and 
! the effectiveness of various drug control programs (e.g., the youth anti-drug
media campaign). 
Actions of the 107th Congress
Fewer drug control bills were enacted by the 107th Congress than by other recent
Congresses.  The 107th Congress did reauthorize the Drug-Free Communities Support
Program for another five years (H.R. 2291/P.L. 107-82).  It also included some of the
provisions of S. 304, a large drug treatment and prevention bill, in the Department of Justice
reauthorization act (H.R. 2215/P.L. 107-273).  The 107th Congress approved FY2002 funding
for the war on drugs in the amount of $18.8 billion, according to the national drug control
budget summary compiled by ONDCP.  It failed, however, to pass the domestic
appropriations bills for FY2003, leaving the drug control agencies (except for the
Department of Defense) operating under a continuing resolution.
Policy Questions and Concerns of the 108th Congress
Drug Control Appropriations
FY2003 Appropriations.  Among the first orders of business of the new Congress
was passage of the 11 remaining FY2003 appropriations bills that were left over from the
107th Congress.  This was accomplished on February 20, 2003, when the Consolidated
Appropriations Resolution, 2003 (H.J.Res. 2) became P.L. 108-7.  The Drug Enforcement
Administration (DEA) received $1.56 billion, 6% less than requested and nearly the same
as the previous year’s amount.  The Office of National Drug Control Policy received $525
million, slightly more than requested and $2 million over the previous year.  The conferees
expressed continuing concern in the conference report about ONDCP’s lack of progress in
developing performance measures of effectiveness for the High Intensity Drug Trafficking
Areas (HIDTA) program.  They also directed ONDCP to provide the appropriations
committees, by June 20, 2003, with a report on problems that exist within the Southwest
Border HIDTA.
FY2004 Appropriations.  The House Commerce, Justice, State (CJS) FY2004
appropriations bill (H.R. 2799) cleared the House and was sent to the Senate on July 23,
2003.  The Senate bill (S. 1585) was reported by the Senate Appropriations Committee on
September 5 and was awaiting floor action when time ran out and the CJS bill was included
in H.R. 2673, the Consolidated Appropriations Act, 2004.  The agreed-upon FY2004
amounts are shown in Table 1.
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Table 1.  CJS:  Selected Drug Enforcement Appropriations
(dollars in millions)









DEA Salaries & Expenses $ 1,550.8 $ 1,558.7 $ 1,584.5 $ 1,661.5 $ 1,661.5
OCDETF $ 367.7 $ 541.8 $ 550.6 $ 580.6 $ 561.0
Weed & Seed $ 58.5  — $ 57.9 $ 51.2 $ 51.2
Drug Courts $ 44.7 $ 68.0 $ 38.1 $ 67.5 $ 50.0
a. FY2003 amounts include a 0.65% rescission.
b. FY2004 amounts include a 0.59% government-wide rescission and a 0.465% reduction applied to DOJ.
ONDCP is included in the Transportation and Treasury appropriations bill.  The House
passed its bill (H.R. 2989) on September 9, 2003.  The Senate passed its version of H.R.
2989, amended, on October 23, 2003.  The FY2004 consolidated appropriations act funded
ONDCP and its programs at levels close to those of the previous year.  It rejected the
Administration’s request for a $20 million increase for the media campaign.  (The House
appropriations report (H.Rept. 108-243, p. 172) had said that any increase in funding for the
media campaign “cannot be justified at this time.”)  It also rejected the request for a $20
million cut in the HIDTA program.  (Further details on all appropriations measures can be
found on the appropriations page of the CRS website.)


















$ 26.3 $ 27.3 $ 28.8 $ 28.0 $ 28.0 $ 27.6
CTAC $ 47.7 $ 40.0 $ 40.0 $ 42.0 $ 42.0 $ 40.0
HIDTA $ 224.9 $ 206.4 $ 226.4 $ 226.4 $ 226.4 $ 208.4
Media Campaign $ 149.0 $ 170.0 $ 150.0 $ 100.0 $ 145.0 $ 145.0
Drug-Free
Communities $ 59.6 $ 70.0 $ 70.0 $ 60.0 $ 70.0 $ 80.0
Other Programs $ 12.9 $ 10.0 $ 10.0 $ 14.0 $ 14.0 $ 10.0
Total $ 520.6 $ 523.7 $ 525.1 $ 470.3 $ 525.3 $ 511.0
Note: Amounts in some columns do not add to total due to rounding.
a. FY2003 amounts include a 0.65% rescission. (The pre-rescission total was $524.0 million.)
b. These amounts will be subject to a 0.59% rescission.
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FY2005 Appropriations.  The President’s FY2005 budget request was submitted to
Congress on February 2, 2004.  Requested amounts for selected drug control agencies and
programs are shown in Tables 1 and 2.
The House passed its version of the CJS appropriations bill (H.R. 4754) on July 8, 2004.
It contains a $77 million increase for DEA, fully funding the Administration request.  It
recommends $561.0 million for the OCDETF program, nearly $10.6 million below the
request but $10.4 million over the previous year’s funding level, after rescissions.
ONDCP Reauthorization
Created in 1988 (P.L. 100-690), reauthorized in 1994 and again in 1998 (P.L. 105-277),
authorization for the Office of National Drug Control Policy expired on September 30, 2003.
A House reauthorization bill (H.R. 2086/Souder) was introduced on May 14, 2003, after a
series of hearings on the issue were held by House Government Reform’s Subcommittee on
Criminal Justice, Drug Policy, and Human Resources.  The subcommittee marked up the bill
and forwarded it to the full committee on May 15, 2003.  The full committee held a hearing
and scheduled a markup for May 22, but the markup was postponed due to disagreements
between the majority and minority over certain of the bill’s provisions.  These disagreements
were resolved at a rescheduled markup on June 5 when the full committee approved an
amendment in the nature of a substitute offered by Mr. Souder and ordered the bill reported,
as amended, to the floor of the House.  The House passed the measure, by voice vote under
suspension of the rules, on September 30, 2003.
H.R. 2086, as approved in the House, would authorize to be appropriated such sums as
necessary to conduct ONDCP’s programs for an additional five years, FY2004 through
FY2008.  It would also authorize specific amounts to be appropriated for the National Youth
Anti-Drug Media Campaign for the same period of time (see following section).  The bill
reaffirms the authority of the ONDCP Director to oversee and coordinate the federal war on
drugs.  It attempts to increase accountability for the achievement of drug policy objectives
by instituting an annual evaluation of the effectiveness of the previous year’s Drug Control
Strategy, including a review of the activities of the many federal departments and agencies
involved in drug control efforts.  The bill contains new funding allocation requirements for
the High Intensity Drug Trafficking Areas (HIDTA) program.  Dropped from the bill as
reported to the full committee were provisions that would have allowed ONDCP to use
HIDTA funds to prosecute medical marijuana users and providers under certain
circumstances and that would seem to permit the “drug czar” to use media campaign funds
to oppose state initiatives to liberalize drug laws.
The Senate’s reauthorization bill (S. 1860) was introduced on November 14, 2003, by
Senators Hatch, Biden, and Grassley.  Like the House bill, S. 1860 would authorize such
sums as necessary to conduct ONDCP’s programs through FY2008 and contains specific
appropriations for the HIDTA program and the media campaign.  The Senate bill would
enhance ONDCP’s authority to coordinate the anti-drug programs of other federal agencies,
require ONDCP to develop specific goals and measurements for evaluating agency
performance, refocus the HIDTA program, and strengthen the technology transfer program
of ONDCP’s Counterdrug Technology Assessment Center.  Unlike the House bill, the Senate
proposal would authorize several drug prevention and treatment provisions taken from an
unenacted measure introduced in the 107th Congress, S. 304.  It also incorporates the
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623, June 2001.
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provisions of two bills introduced earlier in the 108th, the Anabolic Steroid Control Act of
2003 (S. 1780) and a bill to authorize five National Guard counterdrug schools (S. 1785). 
Media Campaign Reauthorization
Originally authorized through FY2002 by the Drug-Free Media Campaign Act of 1998
(P.L. 105-277), reauthorization of the media campaign has been included in H.R. 2086 and
S. 1860, bills to reauthorize ONDCP (see preceding section).  H.R. 2086 would continue the
National Youth Anti-Drug Media Campaign for an additional five years, through FY2008.
H.R. 2086 would authorize appropriations of $195 million for each FY2004 and FY2005 and
$210 million for each FY2006 through FY2008.  S. 1860 would hold the authorization at
$195 million annually for all five years.  The media campaign was funded in amounts
between $180 and $195 million per fiscal year between 1998 and 2002.  Its FY2003  funding,
however, was reduced to $150 million, and it was further reduced to $145 million for
FY2004 (before both years’ rescissions).
Conducted by ONDCP, the media campaign uses all media — from television to the
Internet — to discourage drug use by youth, increase the perception of risk and disapproval
associated with drugs, and encourage parents and other adults to talk to children about drugs.
It has been criticized on grounds of its implementation and effectiveness.  Noting that, with
the latest appropriation, the total media campaign budget now exceeds $1 billion since its
inception, the FY2003 appropriations conference report states (p. 1345): “The conferees are
deeply disturbed by the lack of evidence that the National Youth Anti-Drug Media Campaign
has had any appreciable impact on youth drug use.”  In May 2002, the ONDCP itself released
a report that found little evidence that the youth campaign had had direct, favorable effects
between 2000 and 2001 on drug use by young Americans.  The Government Accountability
Office has also criticized aspects of the campaign.2  Recent ads painting drug users as
supporters of terrorism have been criticized in media stories, some of which present the view
that it is the drug prohibition laws, not the drug users, that create the underground drug
markets, some of the profits of which might find their way into the hands of terrorists.
A hearing on reauthorizing the media campaign was held by House Government
Reform’s Subcommittee on Criminal Justice, Drug Policy and Human Resources on March
27, 2003.  A provision in H.R. 2086 that appeared to allow the ONDCP Director to use
media campaign funds to campaign against the passage of state medical marijuana initiatives
was included in the bill as reported by the subcommittee, but was deleted from the bill during
markup by the full committee.  (For more information and analysis, see CRS Report
RS21490, War on Drugs: The National Youth Anti-Drug Media Campaign.)
The Hinchey-Rohrabacher Amendment
In response to DEA raids on medical cannabis users and providers in California and
other states that have approved the medical use of marijuana under a doctor’s supervision
(see below), Representatives Hinchey and Rohrabacher introduced an amendment to H.R.
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2799, the Commerce, Justice, State appropriations bill for FY2004.   The amendment would
have prevented the Justice Department from using appropriated funds to interfere with the
implementation of medical cannabis laws in the nine states that had approved such use.  The
amendment was debated on the floor of the House on July 22, 2003.  When brought to a vote
on the following day, it was defeated 152 to 273 (66 votes short of passage).  This was the
first congressional vote on the issue of medical cannabis.
The amendment was offered again in the second session of the 108th Congress.  It was
debated on the House floor on July 7, 2004, during consideration of H.R. 4754, the
Commerce, Justice, State appropriations bill for FY2005.  This time, it would have applied
to 10 states, with the recent addition of Vermont to the list of states that have approved the
use of medical cannabis.  It was again defeated by a similar margin, 148 to 268.  The
amendment is expected to be offered again as a measure of support in the House for
marijuana law reform.
DEA Administrator Nomination
On July 31, 2003, Karen P. Tandy was confirmed by unanimous consent in the U.S.
Senate as Administrator of the Drug Enforcement Administration.  Tandy was serving in the
Department of Justice (DOJ) as Associate Deputy Attorney General and Director of the
Organized Crime Drug Enforcement Task Force.  She previously served in DOJ as Chief of
Litigation in the Asset Forfeiture Office and as Deputy Chief for Narcotics and Dangerous
Drugs.  Earlier, she prosecuted drug, money laundering, and forfeiture cases as an Assistant
United States Attorney in the Eastern District of Virginia and in the Western District of
Washington.  The position fell vacant on January 23, 2003, when Asa Hutchinson, DEA’s
previous head, was confirmed as Under Secretary for Border and Transportation Security in
the Department of Homeland Security.
Impact of Homeland Security on Drug Control Agencies
Since the terrorist attacks of September 11, 2001, federal law enforcement agencies
have had to move resources from some of their usual activities to the new mission of
homeland security.  The FBI, for example, has shifted agents from drug investigations to
counterterrorism.  The U.S. Customs Service, Coast Guard, and other agencies are similarly
affected.  The Drug Enforcement Administration is being asked to take up the resultant slack
in drug law enforcement.
The creation of the Department of Homeland Security (DHS) will likely influence the
future conduct of the war on drugs.  Customs, Coast Guard, and the U.S. Border Patrol,
among other agencies, have been incorporated into the new department.  Section 101(b) of
the Homeland Security Act of 2002 (P.L. 107-296), which established the department, states
that the primary mission of DHS is, in part, to “monitor connections between illegal drug
trafficking and terrorism, coordinate efforts to sever such connections, and otherwise
contribute to efforts to interdict illegal drug trafficking.”  Section 878 of the act creates
within DHS the position of Counternarcotics Officer, who will also serve as United States
Interdiction Coordinator, a position previously appointed by the ONDCP director.  The




In light of this significant reallocation of equipment and personnel, the 108th Congress
might choose to consider — possibly through oversight hearings, investigations, and
legislative proposals — how the war on drugs will be affected by the new emphasis on
homeland security, how mission priorities of federal agencies will change, how the creation
of DHS will affect the war on drugs, how to improve information sharing between law
enforcement agencies, and additional questions that have arisen due to the heightened
terrorist threat.
Control of Ecstasy
The Illicit Drug Anti-Proliferation Act of 2003 (S. 226/H.R. 718) was included in
conference as a miscellaneous provision (Section 608) of S. 151, the PROTECT Act (also
known as the Amber Alert Act).  It was signed into law on May 1, 2003 (P.L. 108-21).  The
Illicit Drug Anti-Proliferation Act amends Section 416 of the Controlled Substances Act,
known as the “crack house statute,” to more directly target the producers of dance events, or
“raves,” at which drugs such as Ecstasy (MDMA) are often used.  It shifts the statute’s
emphasis from punishing those who establish places where drugs are made and consumed,
such as crack houses, to those who knowingly maintain “drug-involved premises,” including
outdoor events such as rock concerts.  In addition to the criminal penalties in the original
statute, the amended statute adds a civil penalty, thereby lowering the standard of proof from
beyond a reasonable doubt to a preponderance of evidence.  
The new law also directs the U.S. Sentencing Commission to review and consider
stiffening the federal sentencing guidelines with respect to offenses involving gamma
hydroxybutyric (GHB), the so-called date rape drug; authorizes $5.9 million to be
appropriated to DEA for the hiring of additional special agents to serve as Demand
Reduction Coordinators at the state level; and authorizes such sums as necessary to DEA for
drug education efforts directed at youth, their parents, and others about Ecstasy and other so-
called “club drugs.”
The RAVE act was originally introduced in the 107th Congress (S. 2633/H.R. 5519).
S. 2633 was reported out of committee and placed on the Senate Legislative Calendar.  It was
not called up, however, after being targeted by several civil liberties, drug reform, and dance
culture groups that organized demonstrations and letter-writing campaigns against the
proposal.  These actions resumed when the bills were reintroduced in the 108th Congress and
continue against the new law and the way it is being implemented.  For more information and
analysis, see CRS Report RS21108, Ecstasy: Legislative Proposals in the 107th Congress to
Control MDMA. 
Ballot Initiatives and Budgetary Shortfalls in the States
Recent developments at the state level could attract the attention of the 108th Congress
and lead to hearings and possible legislation.  Forced into a stance of fiscal restraint by
declining revenues, many states are seeking to cut costs by reducing the number of
nonviolent drug offenders in their prisons.  Drug courts and drug treatment programs are
usually seen as money-saving alternatives to imprisonment.  Mandatory minimum sentences
for nonviolent crimes such as drug possession and “three strikes” laws are being revisited by
some state legislatures.  Also, voters in some states have approved initiatives that mandate
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treatment instead of prison for certain drug offenders.  Other state ballot referenda have
approved the use of marijuana for medical purposes.  
According to a December 19, 2002, article in the New York Times, states are reducing
their budget deficits by laying off prison guards, closing prisons, giving inmates early
releases from prison, repealing mandatory minimum sentences, sending drug offenders to
treatment rather than prison, not prosecuting misdemeanor violations, and finding ways
around truth-in-sentencing laws and no-parole policies in order to release convicted felons
early.  “Last week the legislature in Michigan,” the article says, “voted to repeal the state’s
strict mandatory minimum sentencing laws for drug crimes which have led to even life
sentences for possession of cocaine or heroin.”
Since the states collectively spend more money and resources on the drug war than the
federal government, these developments could detract from the country’s overall anti-drug
effort.  Some may argue that it is necessary for the federal government to pick up more of the
tab through grant programs or other forms of aid to the states if it expects the states to
continue the “get-tough” policies of recent years.  Indeed, some state officials view the wars
on drugs and  terrorism as enormous, unfunded federal mandates and would welcome
increased federal assistance.  Large federal budget deficits may, however, constrain new
federal spending.
Souder Amendment to the Higher Education Act
In 1998, the 105th Congress included in its reauthorization of the Higher Education Act
(HEA) an amendment (20 U.S.C. 1091(r)(1)) that denies federal financial aid to any student
convicted of a drug offense.  During the 2001-2002 academic year, according to the
Department of Education, some 43,000 students were denied student loans because of this
provision of law, known as the Souder amendment.  Changes to this provision may be
considered as part of the potential reauthorization of the HEA during the 108th Congress.
Critics contend that the amendment has a greater impact on minorities due to an alleged
racially disproportionate enforcement of drug laws and because minorities are likely to be
more in need of student aid.  A national organization, Students for Sensible Drug Policy, has
arisen in opposition to it, and a House bill, first introduced in the 107th Congress to repeal
it, has been reintroduced in the 108th Congress as H.R. 685 (Frank).  Another House bill in
the last Congress, with Representative Souder as an original co-sponsor, would have changed
the amendment to restrict its application to drug offenses that occur only when the student
is actually receiving student aid.  It has been reintroduced in the 108th Congress as H.R. 696
(Meeks).  The ONDCP reauthorization bills (H.R. 2086 and S. 1860), as well, each contain
a provision designed to encourage the Department of Education to deny loans only to
students who are convicted of drug offenses while actually receiving financial aid.
Executive Branch Actions
The National Drug Control Strategy
In March 2004, President Bush transmitted to Congress the 2004 National Drug Control
Strategy.  Its proposed $12.6 billion budget for FY2005 is dedicated to the three core
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priorities of stopping drug use before it starts, healing America’s drug users, and disrupting
the drug market.
Stopping Drug Use Before it Starts.  The emphasis here is on education and
community engagement to reduce drug use by young people and on drug testing of students.
The 2002 strategy set forth the goals of reducing past-month drug use by youth and adults
in America by 10% in two years and 25% in five years from the baseline established by the
2000 National Household Survey on Drug Abuse.  The 2004 strategy announces that the two-
year goal has been exceeded, with an 11% drop in past-month use of illicit drugs by high
school students between 2001 and 2003, as measured by the most recent Monitoring the
Future survey.  (The baseline was changed from the National Household Survey because
changes in its methodology created a discontinuity between the 2002 survey and previous
years’ data.  ONDCP now measures progress by youth toward the goals by using the
Monitoring the Future (MTF) survey, with the 2000-2001 school year as the baseline.  Since
this survey does not measure adult drug usage, the revised National Household Survey —
renamed the National Survey on Drug Use and Health (NSDUH) — will be used to measure
progress toward the goals by adults, with the baseline being the survey’s 2002 data.  Both
MTF and NSDUH are conducted under the auspices of the U.S. Department of Health and
Human Services.)
Healing America’s Drug Users.  The 2004 strategy estimates that, of the 20 million
Americans who use drugs on a monthly basis, roughly 7 million meet the clinical criteria for
needing drug treatment.  The strategy proposes $2.3 billion for drug treatment, a 6%  increase
over FY2004.  The strategy also announces a new focus on reducing the nonmedical use of
prescription drugs.  Survey data reveal that abuse of legal medicines, especially pain
relievers, is the second leading category of illegal drug use in the United States, after
marijuana.  The development of state-level prescription monitoring programs (PMPs) in the
many states that do not yet have them is one tactic promoted by the 2004 strategy to deal with
this problem.
Disrupting the Drug Market.  The strategy proposes $2.6 billion in FY2005 for drug
interdiction, an increase of 4.5% from FY2004.  Internationally, the strategy intends to
continue to target the supply of illegal drugs in the source countries, and domestically to
promote the use by law enforcement agencies of a single list identifying high-level drug
trafficking targets — the Consolidated Priority Organization Targeting (CPOT) list.  Overall,
55% of the drug control budget is allocated for law enforcement, international programs,
drug-related intelligence spending, and interdiction activities.
The National Drug Control Budget
Many departments and agencies other than ONDCP and DEA are involved in the war
on drugs and are included in the national drug control budget summary, which ONDCP
compiles annually and releases with the National Drug Control Strategy.  ONDCP has
revised its methodology for compiling the drug control budget, as announced in the 2002
strategy, resulting in lower estimates for many drug control agencies and the elimination of
some agencies from the drug control budget altogether.  By including only programs that are
genuinely directed at reducing drug use and excluding agencies that play only a supporting
role in the drug war, ONDCP believes the new drug budget structure will better serve
Congress and the public and bring greater accountability to federal drug control efforts.
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Others, however, say the new budget methodology distorts the true costs of the war on drugs
by excluding the costs of incarcerating drug offenders and other law enforcement activities,
and by exaggerating drug treatment expenditures, thereby making the budget appear to be
more evenly balanced between enforcement and prevention than in previous years, even
though little change has actually taken place. 
ONDCP’s drug control budget summary in the 2002 National Drug Control Strategy,
the last to be prepared using the old, more inclusive methodology, shows nearly $18.1 billion
in final budget authority for FY2001, more than $18.8 billion appropriated for FY2002, and
almost $19.2 billion requested for FY2003.  That strategy also contains a table based on the
proposed new budget methodology.  It revises the FY2003 budget request downward from
$19.2 billion to $11.4 billion, a dramatic measure of the extent to which ONDCP thinks
previous budgets were overstated.
ONDCP’s national drug control budget summary for FY2004 was submitted to
Congress on February 3, 2003.  Prepared using the new methodology, the proposed budget
contained $11.679 billion for drug control funding, with 70% of this amount designated for
three federal departments, Health and Human Services ($3.6 billion), Justice ($2.6 billion),
and Homeland Security ($2.0 billion).
The FY2004 budget request called for strengthening the Organized Crime and Drug
Enforcement Task Force (OCDETF) program by combining the Treasury, Transportation,
and Justice OCDETF programs within the Justice Department and increasing the combined
funding level by 15% over FY2003 levels.  The increases would include $22 million to
expand the Foreign Terrorist Tracking Task Force (FTTTF) to include drug investigation
information gathered by OCDETF agencies, $26 million to expand drug investigations linked
to the Attorney General’s Consolidated Priority Organization Target (CPOT) list, and $10
million to expand drug-related financial and money laundering investigations.  This new
approach  is expected by the Bush Administration to result in a better use of federal resources
leading, in 2004, to a 5% reduction in the availability of drugs on the streets of America.
ONDCP’s composite budget summary for FY2005 was released in March 2004.  It
shows total proposed federal drug-control expenditures of $12.649 billion, an 8.3% increase
over the Administration’s FY2004 request, and 4.7% more than Congress actually
appropriated for FY2004.  Divided among 10 federal departments and agencies, 71% of the
total budget would again go to the departments of Health and Human Services ($3.7 billion),
Justice ($2.7 billion), and Homeland Security ($2.5 billion).  The budget shows 45% going
to treatment and prevention and the rest to law enforcement and interdiction.
Monitoring the Future’s 2003 Study
The Administration has released drug use statistics to show it is moving toward
intended goals.  At an upbeat Washington press conference in December 2003,
Administration officials released the results of the 2003 Monitoring the Future survey of drug
use by 8th, 10th, and 12th grade students in U.S. schools.  Based on a representative sample of
nearly 50,000 students in 392 secondary schools across the country, the results showed the
largest reduction in past month use of an illicit drug by youth in more than a decade.
Between 2001 and 2003, the survey recorded an 11 % decline, from 19.4% to 17.3%.  The
proportions of 8th, 10th, and 12th graders reporting that they used an illegal drug in the
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Washington.
4 Dale Gieringer, “The Acceptance of Medical Marijuana in the U.S.” Journal of Cannabis
Therapeutics, vol. 3, no. 1 (2003), pp. 53-67.  The author now estimates that there are more than
100,000 medical marijuana patients in California alone (personal communication dated Apr. 30,
2004).  Oregon’s Department of Human Services reported 8,975 registered medical marijuana
patients as of Apr. 1, 2004, see [http://www.dhs.state.or.us/publichealth/mm/data.cfm].  
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previous year now stand at 16%, 32%, and 39%, respectively.  The proportions saying they
have used an illegal drug at least once in their lives stand at 23%, 41%, and 51%.  
DEA’s Proposed Rule on Industrial Hemp
The term “industrial hemp” refers to cannabis plants that are grown to produce fiber and
oil used in industrial products such as paper, rope, clothing, industrial solvents, and animal
feed.  Other hemp products include foods such as nutrition bars, salad dressings, and beer,
and personal care products such as shampoo, creams, and lotions.  In October 2001, DEA
published three interpretive rules in the Federal Register (66 FR 51530-51544) that would
have made illegal any hemp products that could cause THC, a psychoactive ingredient of
marijuana, to enter the human body.  Manufacturers and distributors of THC-containing
hemp products made for human consumption were given 120 days, until February 6, 2002,
to dispose of such products.  The Hemp Industries Association (HIA) contested the rules in
court, and the U.S. Ninth Circuit Court of Appeals temporarily blocked their implementation.
More than 115,000 public comments against the new rules were submitted to the DEA.  The
final rule was published in the Federal Register on February 21, 2003.  It would have banned
the sale of all hemp food products by April 21, 2003.  The Hemp Industries Association once
again requested a stay, which the Ninth Circuit granted on April 16, 2003.  On February 6,
2004, HIA and the other plaintiffs won their lawsuit against DEA when a three-judge Ninth-
Circuit panel ruled unanimously that DEA cannot regulate non-psychoactive hemp products
and permanently blocked enforcement of the final rule.  The opinion in Hemp Industries
Association v. DEA, Case No. 03-71366, can be found at [http://www.ce9.uscourts.gov]. 
DEA Raids on Medical Cannabis
Ten states — beginning with California in 1996 — have decriminalized some form of
medical marijuana use.3  According to a 2002 study published in the Journal of Cannabis
Therapeutics, 30,000 California patients and another 5,000 patients in eight other states were
estimated to possess physician’s recommendations to use cannabis medically.4  In response
to this situation, DEA agents have raided and shut down medical marijuana providers in
several states, backed by a 2001 U.S. Supreme Court ruling affirming that federal drug laws
take precedence over state laws and barring doctors from prescribing illegal drugs.
Opposition in defiance of the DEA tactics has arisen in California cities such as San
Francisco and Santa Cruz.  In November 2002, nearly 7 out of 10 San Francisco voters
approved Proposition S, which encourages the city’s Board of Supervisors to enact a law
authorizing the cultivation and distribution of medicinal marijuana by the city government.
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More recently, on April 23, 2003, the city and county of Santa Cruz, along with seven
medical marijuana patients, filed a lawsuit in San Jose federal district court in response to
DEA’s September 2002 raid on the Wo/Men’s Alliance for Medical Marijuana (WAMM).
The suit was reportedly the first court challenge to be brought by a local governmental entity
against the federal war on drugs.  In the most recent development in this matter, the court
ruled on April 21, 2004, that the plaintiffs had demonstrated irreparable harm and a
likelihood of success in their argument that the Controlled Substances Act, as applied to the
cultivation of marijuana plants for personal medicinal use in compliance with California’s
medicinal marijuana statute, is an unconstitutional exercise of Congress’s Commerce Clause
power.  The court granted the plaintiffs’ motion for a preliminary injunction, thereby
allowing WAMM, for now, to resume growing and producing marijuana medications for its
approximately 250 member-patients with serious illnesses, pending the final outcome of the
case.  This most recent court order, along with other documents in the ongoing matter of
Santa Cruz v. Ashcroft, can be found at [http://www.drugpolicy.org/homepage.cfm].
LEGISLATION
Section 608 of P.L. 108-21 (S. 226/Biden)
Illicit Drug Anti-Proliferation Act of 2003.  Amends the crack house statute (Sec. 416
of the Controlled Substances Act) to more directly target the promoters of “raves” at which
drugs such as Ecstasy (MDMA) are widely used, as discussed above.  S. 226 was introduced
January 28, 2003, and referred to the Committee on the Judiciary.  Included in conference
as a miscellaneous provision (Sec. 608) of S. 151, the PROTECT Act, a child protection act
that became P.L. 108-21 on May 1, 2003.
Section 5025 of H.R. 10 (Hastert)
9/11 Recommendations Implementation Act.  Amends Sec. 878 of the Homeland
Security Act of 2002 (P.L. 107-296) to create in DHS an Office of Counternarcotics
Enforcement to coordinate federal efforts to stem the flow of illegal drugs into the United
States.  Introduced on September 24, 2004, and referred to multiple committees.
H.R. 345 (Bartlett)
Powder-Crack Cocaine Penalty Equalization Act of 2003.  Amends the Controlled
Substances Act and the Controlled Substances Import and Export Act to reduce the amounts
of powder cocaine necessary for specified mandatory minimum sentences so that they equal
those for crack cocaine.  Introduced January 27, 2003, and referred to the Committee on the
Judiciary, and the Committee on Energy and Commerce.
H.R. 685 (Frank)
Amends the Higher Education Act of 1965 to repeal the provisions prohibiting persons
convicted of drug offenses from receiving student financial assistance.  Introduced February
11, 2003, and referred to the Committee on Education and the Workforce.
H.R. 696 (Meeks)
Amends the Higher Education Act of 1965 to restrict the disqualification of students for
drug offenses to those students who committed offenses while actually receiving student
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financial aid.  Introduced February 11, 2003, and referred to the Committee on Education and
the Workforce.  (H.R. 2086 and S. 1860 contain similar provisions.)
H.R. 1717 (Farr)
Truth in Trials Act.  Amends the Controlled Substances Act to allow persons being tried
for marijuana offenses to use in their defense evidence that the marijuana-related activities
in question were in compliance with state law regarding the medical use of marijuana.
Introduced on April 10, 2003, and referred to the Energy and Commerce Committee and the
Judiciary Committee.
H.R. 2086 (Souder)
Office of National Drug Control Policy Reauthorization Act of 2003.  Introduced  May
14, 2003, and referred to the Committee on Government Reform, and in addition to the
Committees on the Judiciary, Energy and Commerce, and Intelligence (Permanent Select).
The Government Reform Subcommittee on Criminal Justice, Drug Policy, and Human
Resources ordered the bill reported, as amended, to the full committee May 15, 2003.  The
full committee marked up the bill June 5, 2003, and ordered it reported, as amended, to the
floor of the House.  The bill, as amended, passed the House by voice vote September 30
under suspension of the rules.
H.R. 2233 (Frank)
States’ Rights to Medical Marijuana Act.  Transfers marijuana from Schedule I to
Schedule II of the Controlled Substances Act (CSA) and prohibits enforcement of the CSA
with regard to medical marijuana in states that permit physicians to prescribe or recommend
marijuana for medical use.  Introduced on May 22, 2003, and referred to the Committee on
Energy and Commerce.
S. 1780 (Biden)
Amends the Controlled Substances Act to clarify the definition of anabolic steroids and
to provide for research and education activities relating to steroids and steroid precursors.
(S. 1860 contains similar provisions.)  Introduced October 23, 2003, and referred to the
Committee on the Judiciary. 
S. 1785 (Grassley)
Formally authorizes and creates a separate budget account for five counterdrug schools
now operated by the National Guard to train law enforcement personnel and community
antidrug activists.  Authorizes $30 million for the schools for each FY2004 through FY2008.
(S. 1860 contains similar provisions.)  Introduced and referred to the Armed Services
Committee October 24, 2003.
S. 1860 (Hatch)
Office of National Drug Control Policy Reauthorization Act of 2003.  Introduced
November 14, 2003, and referred to the Committee on the Judiciary.
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